SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter H. Proctor who wrote (161)7/7/1997 6:26:00 PM
From: CYBERKEN   of 670
 
The cash value and book value premiums indicate that investors have to be convinced that Procyte can successfully market their approved products. The current price puts a negative value on this. Marketing efforts usually take several quarters to show potential success. Therefore, future appreciation of the stock is contingent on them being able to announce sales above (the very low) expectations. The prevailing opinion on these threads is that the products are good ones. Perhaps Procyte will be able to get them well established in the marketplace.
If so, investors will not only reward that, but probably put a positive value on pipeline products.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext